Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Qlife – Company introduction

By Olivier de GoeijDigital Marketing Manager

Meet Qlife’s CEO Thomas Warthoe presenting an introduction to the company.
The event takes place on the 26th of October at 1 pm CET.
 
Qlife’s home diagnostic platform Egoo Health addresses the following trends within healthcare:
 
Healthcare decentralization
Chronic diseases in the increasing ageing population
Lifestyle diseases
 
In the trend for home diagnostics, the company offers a very compelling solution, Qlife already has it CE approved with sales today; the next step is chronic diseases with a market potential of more than 50 mio. patients in the EU, and ultimately sales directly to all people and consumers.
 
Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases.
Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, was CE marked for professional use in early 2020. The company has patent protection for key parts of its technology.
Qlife Holding AB is listed on Nasdaq First North Stockholm with the ticker QLIFE.
HC Andersen Capital receives payment from Qlife for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup 4.55PM 12-oct-2022.

Recent videos

Herantis Pharma Plc, Phase 1b biomarker data webcast
08.01.2026 klo 12.00 Herantis Pharma
Investor Day | Nov. 24, 2025
23.12.2025 klo 12.00 United Bankers
Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025 klo 12.00 Talenom
Investing in the life science sector
18.12.2025 klo 08.47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
16.12.2025 klo 09.30 Aiforia Technologies
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.